{"name":"Galecto Biotech AB","slug":"galecto-biotech-ab","ticker":"","exchange":"","domain":"","description":"Galecto Biotech AB is a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for fibrosis and cancer. The company's pipeline includes five drug candidates, with several in early to mid-stage clinical trials targeting various therapeutic areas.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"GB0139","genericName":"GB0139","slug":"gb0139","indication":"Other","status":"phase_2"},{"name":"Inhaled TD139","genericName":"Inhaled TD139","slug":"inhaled-td139","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"GB0139","genericName":"GB0139","slug":"gb0139","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Inhaled TD139","genericName":"Inhaled TD139","slug":"inhaled-td139","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOVExJQ0tfMFJObmFMTkhzZ1FvYlFwN2VsVFN6bUQ5b3ZzOHBtd3VuUjE0Rjltc2M0emFHVG92TmRYUE1ZVmVqYW04ZVhuR1IyWHhSdXBKUGlnRnJldUdCbXUzYURucWRnbFR4SDZaajFmYXlyMUIxdmVieWRKdUtmM3RxOS1IMTgyb0V4bWt3Q1hNOXBpVmpudg?oc=5","date":"2026-03-20","type":"pipeline","source":"openPR.com","summary":"Myelofibrosis Pipeline 2026: Therapies Under Investigation, - openPR.com","headline":"Myelofibrosis Pipeline 2026: Therapies Under Investigation,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxOb2FpNnlvQ2NMX0ZSTnZkdGtFUXhFUzhyRXA4SjJQcF9uOHZRaWJDZ1hDUnZ0T0pLWmthYWRmM2NGTVNDZkFOQnZPbFlhY0lNUnJmNkpnYll3eERNOW8wVS1VMFV2QnE5bWMzZDBFcGduUUpqaDBpZGtSNlE1SDVDRTMxNENyMFJud3F0S3pyUi1rMHZhZ1JhUHNtc1VScWZoZkszc0lMYVFOaWhpUk5QMVhtbl92VU9WWlJnR2VwSnp5elhiV1hENHVXV0FpemhUa29jd0JxUGJqWnVFcTZ2dnAxWDQ4LTN4T3pyZ0xIcWtJdFk3dFVqaEp2cng2b0lSOTd0YTVQNGFXMzZteTA0N3VpbDg0U3dDT2J2QVliNGdPUldNa0Zndi1mRzZ3a3h1dHc?oc=5","date":"2026-02-09","type":"trial","source":"GlobeNewswire","summary":"Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline - GlobeNewswire","headline":"Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxPODR6a0JUUjQ2d3pHa2c0M3gtN2ZRMDVGandaRFJha3VIMjg3OEdjWTRZTk1uMlV4Z3ktQUhXZGgxNW9oYmRPQ29NSlpwYklHenlyOElhTnhHTENKZldhZ1JiZ3RWU19CLW5vRUVGWEpneEs4dGY5V1gxRnhHanA2Ni1qQno5SnkyZG40dWxyYWVzVFM4Z2hKaHJqTlg2OEkzTnhMd0hveW5vdEhiRENMVEFxTlVtV1ZwejdjVHhnVlYtR1lhbDVuRzU3YlVETDR3bjhhZm40LWVNcUpKQVdpY2FHZl9JTWQ2VDVRR19KdjFVd1o5RUQzOERDMkZQcEpLWTNwZVJtcjgzR2ppYUJRS01kMnUxOUpLSDlwWFVHT19EaVZDSFhaS2F5cHpNa0MwZjcwVXY1X0dSejgwNUE?oc=5","date":"2025-01-28","type":"trial","source":"GlobeNewswire","summary":"Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust - GlobeNewswire","headline":"Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQRE0tVHFDTkFjR0pnOEVHY2RxaEFtc3Nna2piVk9FZEg3VjhhOTJSb2FvWGpRdFhJRlFvNVdOV3FfYkJTNGVaSEVGbVpPWjh3REFta3NxM2tSckNkX3dBNVFNWTNUeHdtcVRtdDc0bTMzMVNlTHF6MnNDTUFDcWMxV3dzYmNJbWxUbDJSeGhFdC1wMnU5bG9hZ1h5MDRHM0tWS09WM0xZWkkzUXpOZlNEc25QVmlRNndvZExKZjV0VWFBVlNPTXM1SUJ3em11VzByRUhndk1wRE1ILWVMOUxjXzBXYw?oc=5","date":"2024-09-09","type":"pipeline","source":"PR Newswire","summary":"Idiopathic Pulmonary Fibrosis Treatment Drug Market to Increase 2 Folds by 2034 | DelveInsight - PR Newswire","headline":"Idiopathic Pulmonary Fibrosis Treatment Drug Market to Increase 2 Folds by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxNVGhpZEFiUzhvRU5fTEFRVm51dXgyT1E2WDVDZ1UxYTJQdi1UV0w4eVhwSGN4Z2wyUk1nUmdSbGZXcGpzb2RzNTNwNWpTTHZiSUJ2ZFlyMUFxMzFXcDNEZTNnd1k0ZkRTVW11UW01SEJval8wc3RaQmJ4UGJYeFAtOXBQcmxSMWYxX3BEejViZEQ0NU5sdldoNWlCVnRpWEVUZVZ5Mm5ScXdtbGVXR2JmSVhia091d1QyRDZ4UXE2cHlNMXpJaUtKX3FYZDB5ZkZfT3k2dFREMzBRdnlWTnNmOFItYy16VjFVMUNhYUFvMlZpbnBzeUdPWHN2R1YxbEwzU1JlaDhKSldqTWs?oc=5","date":"2024-04-03","type":"pipeline","source":"PR Newswire","summary":"Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveInsight - PR Newswire","headline":"Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveIn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxQWHNuMmYyU0dYeFRna1RXMU02ck5fSklQZllyVFpBREZXNTRGOHJDejZGcGx4RzBFQzhXeDlpalAyOE8xWTlyTmZVUDAyZkhPV2xoNTZlRkRwOHBhUk14VnBOcEhQN3ZOaDdkb3lJZEdsaVRjWk9mS0tDRGU0VDRyQ0JYX0FlSHh5RjFaeWpab0hiNkwwZVk5NHhPNndOTGFPcWRpRjZJUllGVklqNEtZWnZGNVJidWJQbHA5SzYxRmJPT3JSdDZhZ0hKRjJFRmNUek9WUnU4R3NSOWt4bDhWTUI4RzB5WWYxXzRHa3RhbDU2a3UxY3RXYlBLbHNlLXU3bnNwazZEbS15MXFSdEVDaE5ZU0pfb0N2YXB0eWRTN0dQb3lzTTdaek5EMEFGaDVheng3ZFJkYw?oc=5","date":"2023-05-25","type":"trial","source":"PR Newswire","summary":"Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxOZmdmY1QwbUVfcXg3YXYtUXlLUjRXN1d2MGYtOVM3NmptQ3RvT2pvQldLUzVWX0E2dEl2RTREa1FBc3NOemlnSmVMaUVtZUJ0SmVzanNsMXFIRVZDbTZZdmVXRDJkYjZvLUlPbVJIWFdjOG9VNVRKNnNuSlh4anZaLUZzeHp0ZnY1QmJaOGtKcWZaRnNLS1lKbmUtbnRvYklES280TFRjRUYxeEw4RjFPa3hXeEhOZHJYQ2ltLUR5Q0R6akdSWTVobmRGRlJEUQ?oc=5","date":"2015-01-28","type":"earnings","source":"European Pharmaceutical Review","summary":"Bristol-Myers Squibb reports fourth quarter and full year 2014 financial results - European Pharmaceutical Review","headline":"Bristol-Myers Squibb reports fourth quarter and full year 2014 financial results","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}